{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-23-006099","form_type":"8-K","ticker":"VNRX","cik":"0000093314","company_name":"VOLITIONRX LTD","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.081324+00:00","generated_at":"2026-06-11T13:42:29.373299+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"VolitionRx submits Breakthrough Device request to FDA for Nu.Q sepsis test; H1 revenue exceeds full-year 2022","bullets":["Submitted Breakthrough Device Designation Request to FDA for Nu.Q technology in sepsis in June 2023.","H1 2023 total revenue $366,000, exceeding full-year 2022 revenue; Nu.Q Vet sales grew five-fold.","Cash $19.7M at June 30, 2023, vs $10.9M at 2022 year-end; raised $17.6M net in June public offering.","Expects $13M in milestone payments from Heska and additional non-dilutive Belgian agency funding.","Centers of Excellence for Nu.Q NETs progressing; first clinical paper submitted for peer review."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-23-006099","json":"https://secwatch.observer/filing/0001477932-23-006099.json","markdown":"https://secwatch.observer/filing/0001477932-23-006099.md","text":"https://secwatch.observer/filing/0001477932-23-006099.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/93314/000147793223006099/0001477932-23-006099-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/93314/000147793223006099/vnrx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T13:42:29.373299+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9e0fd43ce9ccf099439b5e9f0a2064823a88f1c5","claim":"VOLITIONRX LTD reported financial results for second quarter ended June 30, 2023.","evidence_excerpt":"VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”) today announced financial results and a business update for the second quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/93314/000147793223006099/0001477932-23-006099-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}